Stifel Reiterates Hold on Vertex Pharmaceuticals, Maintains $373 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has reiterated a 'Hold' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $373.

November 22, 2023 | 6:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst Paul Matteis reaffirmed a 'Hold' rating on Vertex Pharmaceuticals with a price target of $373.
The reiteration of a 'Hold' rating and maintenance of the current price target suggests that the analyst sees no immediate change in the company's valuation or prospects. This is likely to have a neutral short-term impact on the stock as it does not alter the investment thesis for current or potential investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100